Matt Henriksen

Yeah.

And, you know, one of the things I've noticed as well is, you know, between G5, G6, G7, you know, it's a four-year product cycle, give or take.

So we're December of 2022 as G7 comes out.

But I'm curious about the product cycle as these technologies get more and more sophisticated.

I mean, because with the G7, you already have gotten the MARD or the mean absolute relative difference, right?

You've gotten that down from the 10% range to now 8%, sub 8%.

Each incremental improvement seems like it's going to require more and more technology or higher technology, higher developments.

Is that something to consider as we kind of think about these product cycles as because of how much improvement has already taken place between G5 and G7, just that incremental improvement takes a little more time in that product cycle?

Yeah, that's all great.

And as we close out, I always like to say, what inning do you think we are in utilizing this technology?

You've been here for 20 years.

You're starting now as the CEO role.

But you already mentioned you were in the early innings.

You talked about the 10 million patients on CGM versus the nearly 600 million patients that could potentially benefit from it.

So all those make sense of early, early innings.

But how

How do you see that playing out over the next few years as we go from the maybe, let's say, top of the second to the bottom of the second?

And, you know, one number that caught my attention, too, in the pre-announcement was you were expecting to get $1 billion in free cash flow in 2026.

So how do you start using that dry powder to help get you from the top of the second to the bottom of the second inning?

Yeah, and I think that kind of goes back to, you know, I listened to your first presentation earlier this month, or now we're in January, back in January, and you started it off with the impact of metabolic health.